AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • March 27th, 2020 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Amended and Restated Incentive Compensation Agreement, dated as of March 25, 2020, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Bobbi Jo Brockmann (the “Executive”), and replaces and supersedes in its entirety the Incentive Compensation Agreement, dated as of April 11, 2019, between the Company and the Executive.
SEVERANCE AGREEMENTSeverance Agreement • March 27th, 2020 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Severance Agreement, dated as of March 25, 2020, is by and between IMMUCELL CORPORATION, a Delaware corporation (the “Company”) and MICHAEL F. BRIGHAM (the Executive”).
IMMUCELL CORPORATION INCENTIVE STOCK OPTION AGREEMENTOption and Incentive Plan • March 27th, 2020 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Option is specifically subject to all of the terms and conditions of the 2017 Plan with the same force and effect as if fully set forth in this Option. In the event of any inconsistency or misunderstanding with respect to the terms of this Option, as compared with the provisions of the 2017 Plan, the provisions of the 2017 Plan shall control and prevail.
